Published on
December 10, 2025
- 12:30 GMT
LAPIX Therapeutics Reports Positive Bioequivalence for Oral Capsule and New Safety Milestones in the LPX-TI641 Program
The new oral capsule advances into Phase Ib studies as GLP data establish a new NOAEL, expanding safety margins for LPX-TI641 development. CAMBRIDGE , MA, UNITED STATES, December 10, 2025 /EINPresswire.com/ -- LAPIX Therapeutics, Inc. (“LAPIX”), a …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Science
...
